Medical device company Integra LifeSciences (NASDAQ: IART) will be announcing earnings results this Wednesday before market open. Here’s what to look for.

Integra LifeSciences met analysts’ revenue expectations last quarter, reporting revenues of $418.8 million, flat year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations.

Is Integra LifeSciences a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Integra LifeSciences’s revenue to grow 2.6% year on year, slowing from the 5.6% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Integra LifeSciences has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Integra LifeSciences’s peers in the healthcare equipment and supplies segment, only Neogen has reported results so far. It exceeded analysts’ revenue estimates, delivering year-on-year sales growth of 6.5%. The stock was down 2.3% on the results.

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Integra LifeSciences is down 13.8% during the same time and is heading into earnings with an average analyst price target of $18 (compared to the current share price of $13.44).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.